Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginInterest Coverage RatioNet MarginOperating MarginReturn on SalesTimes Interest Earned

KalVista Pharmaceuticals (KALV) Equity Ratio (2017 - 2024)

KalVista Pharmaceuticals' Equity Ratio history spans 10 years, with the latest figure at 0.56 for Q4 2024.

  • For Q4 2024, Equity Ratio changed N/A year-over-year to 0.56; the TTM value through Dec 2024 reached 0.56, changed N/A, while the annual FY2024 figure was 0.88, N/A changed from the prior year.
  • Equity Ratio for Q4 2024 was 0.56 at KalVista Pharmaceuticals, down from 0.83 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.91 in Q2 2020 and bottomed at 0.56 in Q4 2024.
  • The 4-year median for Equity Ratio is 0.87 (2023), against an average of 0.83.
  • The largest YoY upside for Equity Ratio was 10.53% in 2020 against a maximum downside of 1.3% in 2020.
  • A 4-year view of Equity Ratio shows it stood at 0.86 in 2020, then increased by 2.71% to 0.88 in 2021, then fell by 6.75% to 0.82 in 2023, then plummeted by 32.41% to 0.56 in 2024.
  • Per Business Quant, the three most recent readings for KALV's Equity Ratio are 0.56 (Q4 2024), 0.83 (Q4 2024), and 0.86 (Q3 2024).